Skip to main content
. 2026 Nov 2;14:1967139. doi: 10.3389/fped.2026.1967139

Table 3.

Covariate-adjusted linear regressions of maternal 25(OH)D3 concentrations dichotomized as “sufficient” vs. “insufficient” at 30 ng/mL threshold recommended by the Endocrine Society's 2011 guidelines† and neurodevelopmental outcomes (N = 252).

Neurodevelopmental outcome measure Unstandardized beta coefficient SE 95% CI p-value
WPPSI-IVCDN FSIQ −0.12 1.97 −3.97, 3.74 0.95
NEPSY-II Phonological Processing 0.10 0.46 −0.79, 1.00 0.82
NEPSY-II Speeded Naming 0.29 0.41 −0.51, 1.10 0.48
MABC-II Total 0.52 0.44 −0.34, 1.38 0.24
BASC-II Internalizing Problems 1.25 1.36 −1.41, 3.91 0.36
BASC-II Externalizing Problems 0.73 1.23 −1.67, 3.13 0.55

Covariates are the same as those included in the linear regressions of continuous maternal 25(OH)D3 concentrations and neurodevelopmental outcomes.

†

The Endocrine Society's 2011 30 ng/mL threshold refers to total 25(OH)D; this total measure could not be calculated in the present study and thus maternal 25(OH)D3 concentrations were used in lieu of the total. These analyses should be a considered a historical sensitivity analysis to improve interpretation across the literature as the 2024 guidelines no longer endorse using this threshold.